​

Funding Round

Series B - WindMIL Therapeutics

Series B - WindMIL Therapeutics

Investment Firm

Overview

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.

Announced Date

Jun 18, 2018

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Qiming Venture Partners

Qiming Venture Partners

Qiming Venture Partners is a early_stage_venture and late_stage_venture and private_equity and seed firm.

Participant Investors

5

Investor Name
Participant InvestorFoxKiser
Participant InvestorMedivate Partners
Participant InvestorDomain Associates
Participant InvestorCamden Partners
Participant InvestorQiming Venture Partners

Round Details and Background

WindMIL Therapeutics raised $32500000 on 2018-06-18 in Series B

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 18, 2018
Series B - WindMIL Therapeutics
5-32.5M
Apr 07, 2016
Series A - WindMIL Therapeutics
1-10.0M

Recent Activity

There is no recent news or activity for this profile.